ISHLT Lifetime Achievement Award
As the recipient of the 2022 ISHLT Lifetime Achievement Award, Valantine becomes the third member of Stanford Medicine to receive this significant honor. This recognition speaks to her lifelong commitment to advancing cardiovascular science and patient care.
ISHLT grants this award annually to an individual with an unparalleled contribution or advancement within the field of heart and lung disease. Recipients have distinguished themselves through significant work toward improving patient care.
Champion for diversity and inclusion
Valantine has been a powerful advocate for diversity and inclusion for decades, earning her the ACC recognition for this crucial aspect of the cardiovascular profession. The ACC grants the Pamela S. Douglas Distinguished Award to a member who has championed inclusivity in the workforce. Awardees are a voice that engages diverse perspectives and backgrounds in the cardiovascular field.2
- Additional training and tools to combat conscious and unconscious bias and racism
- Advising leaders in the Department of Medicine on how to further advance faculty diversity in gender, race, and ethnicity
- Gathering diverse groups to conduct team science and apply for NIH grants
Throughout her career, Valantine has led research to understand differences and disparities across racially diverse patient populations. Her continued efforts will enhance Stanford Medicine’s reputation as an institution committed to equity for all.
Pioneer in heart transplantation research
Stanford Health Care was the first U.S. transplant center to perform cardiac transplantation. And in the 1980s, Valantine was on the front lines of this exciting new procedure with her colleagues at Stanford Health Care.
Today, more than 30 years later, her passion for improving heart transplantation continues. Alongside Stanford Medicine scientists, Valantine recently developed donor-derived cell-free DNA technology, a novel tool used to monitor organ transplant rejection. Her research continues to establish this blood biomarker as a reliable indicator of allograft injury early, during acute rejection, and to help distinguish different types of rejection.
Results of the heart transplant study reveal that donor-derived cell-free DNA detects acute rejection earlier than the standard biopsy. Read the full article in Circulation.
The study came after initial findings from the Genomic Research Alliance for Transplantation (GRAfT) replicated the technology’s abilities. Created by Valantine, GRAfT is a consortium of five heart and lung transplant centers in Washington, D.C. GRAfT enrolls and actively follows transplant patients, almost half of whom are African Americans. The substantial inclusion of racial ethnic groups in GRAfT will allow for further studies by Valantine and her colleagues to understand why African Americans face a particularly high risk of organ rejection, with the goal of developing new anti-rejection drugs.
Stanford Health Care continues to be recognized as a top-ranked heart transplant and heart failure hospital for its high volumes, excellent outcomes, innovations, and expertise. Stanford Health Care is ranked among the nation's top 10 Cardiology & Heart Surgery programs.5
Learn more about Hannah Valantine, MD and the Stanford Cardiovascular Institute.